Pharmacokinetics of Once versus Twice Daily Lamivudine and Abacavir in HIV-1 Infected Ugandan Children in the ARROW trial.

Abstract

41 HIV-infected children in Uganda, not previously treated with antiretroviral drugs, were treated with twice-daily lamivudine and abacavir for 36 weeks, and the pharmacokinetics of both drugs in the blood was studied over a 12-hour period following that day's dose. The children were then switched to a once-daily regimen for 4 weeks, and a similar pharmacokinetic investigation (with an additional sample 24 hours post-dose) was done. For both drugs, the area under the concentration-time curve was similar in the twice-daily and once-daily regimens; the maximum concentration was 76% and 64% higher for lamivudine and abacavir respectively under the once-daily regimen. Most of the patients and their caregivers preferred the once-daily regimen which, it is concluded, appears to be a feasible alternative to the twice-daily regimen.

Citation

Musiime, V.; Ferrier, A.; Kitaka, S.B.; Odongo, F.; Kekitiinwa, A.; Thomason, M.J.; Lee, D.Y.; Burger, D.; Thoofer, N.; Nahirya-Ntege, P.; Nathoo, K.J.; Snowden, W.; Musoke, P.; Mugyenyi, P.; Walker, A.S. Pharmacokinetics of Once versus Twice Daily Lamivudine and Abacavir in HIV-1 Infected Ugandan Children in the ARROW trial. Presented at 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-22 July 2009, and 1st International Workshop on HIV Pediatrics, 17-18 July 2009, Cape Town, South Africa. (2009)

Pharmacokinetics of Once versus Twice Daily Lamivudine and Abacavir in HIV-1 Infected Ugandan Children in the ARROW trial.

Help us improve GOV.UK

Don’t include personal or financial information like your National Insurance number or credit card details.